VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2021 | 10 year follow up of rituximab and lenalidomide in low tumor burden FL

Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from a follow up from an open-label Phase II trial (NCT00695786) of rituximab and lenalidomide (R2) in patients with low tumor burden follicular lymphoma (FL). After 10 years follow-up, a majority of patients treated with R2 remained in remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter